pharma
AstraZeneca increases drug stockpile in preparation for no-deal Brexit
July 18, 2018Research and Development AstraZeneca, brexit, no-deal, pharma, stockpiling
The Anglo-Swedish drug giant AstraZeneca is set to increase its stockpile of drugs in both the United Kingdom and the …
Novartis follows Pfizer’s lead, pledges no price hikes in 2018
July 18, 2018Research and Development, Sales and Marketing Novartis, Pfizer, President trump, Trump, US, pharma
Following US pharma giant Pfizer’s clash with President Donald Trump after it was called out on Twitter for hiking the …
AbbVie and Mylan reach US marketing agreement for Humira biosimilar
July 18, 2018Research and Development, Sales and Marketing AbbVie, Humira, Mylan, US, pharma
AbbVie and Mylan have announced that they have both signed a licensing agreement for the former’s proposed biosimilar version of …
Researchers successfully minimise diabetes drug side-effects in animal models
July 17, 2018Manufacturing and Production, Research and Development FDA, diabetes, pharma, type 2 diabetes
Researchers at the University of Pennsylvania and Syracuse University have modified a key ingredient of current diabetes drugs to produce …
Roche flu drug proves efficacy at Phase 3, but enough to beat Tamiflu generics?
July 17, 2018Manufacturing and Production, Research and Development Roche, Tamiflu, baloxavir marboxil, flu, influenza, pharma
Roche is celebrating the news that its investigational influenza drug baloxavir marboxil performed well at Phase 3, meeting its primary …
J&J stops Invokana trial early after success in kidney disease and type 2 diabetes
July 17, 2018Manufacturing and Production, Research and Development J&J, JJ, Janssen, Johnson & Johnson, invokana, kidney disease, pharma, renal, type 2 diabetesm diabetes
Johnson & Johnson and research arm Janssen have taken the decision to terminate a Phase 3 trial evaluating the efficacy …
Recruitment and retention: How can we do better?
July 16, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing clinical trials, feature, patient recruitment, patients, pharma
In pharma R&D, data is king, but consistent struggles with patient retention is undermining the integrity of clinical findings. Matt …
FDA expands Pfizer and Astellas’ Xtandi into castration-resistant prostate cancer
July 16, 2018Sales and Marketing Astellas, Cancer, FDA, Pfizer, US, Xtandi, pharma, prostate cancer
Astellas and Pfizer have revealed that their androgen receptor inhibitor Xtandi (enzalutamide) has received approval from the FDA to expand …
FDA approves first smallpox therapy to defend against bioterrorism
July 16, 2018Sales and Marketing FDA, pharma, smallpox
The FDA has announced that it has awarded marketing authorisation to SIGA Technologies’ TPOXX (tecovirimat) in the first approval of …
Takeda’s Ninlaro clears Phase 3 endpoint as maintenance therapy in multiple myeloma
July 12, 2018Medical Communications, Research and Development Ninlaro, Takeda, multiple myeloma, pharma
After making headlines with its mammoth deal to acquire Shire earlier this year, Takeda has emerged with new Phase 3 …
Otsuka snaps up Visterra in $430 million deal
July 12, 2018Research and Development, Sales and Marketing Otsuka, Visterra, acquisition, pharma
Otsuka Pharmaceutical has announced it has reached a definitive, board-approved agreement with Visterra to acquire the latter company in an …
Novartis pulls out of antibiotics, cuts 140 staff
July 12, 2018Sales and Marketing Antibiotics, Novartis, pharma, staff cuts
Novartis has announced that it is to terminate its research operations into antibiotics and antivirals in a reorganisation effort that …
NICE approves treatment for rare and deadly childhood cancer
July 11, 2018Sales and Marketing Cancer, NICE, UK, neuroblastoma, pharma
NICE has recommended that monoclonal antibody dinutuximab beta be used in treating high-risk neuroblastoma – a rare and deadly form …
Celgene and Acceleron’s blood disorder drug smashes endpoints at Phase 3
July 11, 2018Research and Development Acceleron, Celgene, beta-thalassemia, luspatercept, pharma
Celgene and Acceleron have lifted the curtain on new Phase 3 data for their erythroid maturation agent (EMA) luspatercept, confirming …
Wellcome Trust announces £250m fund for high risk ideas
July 11, 2018Research and Development 250 million, Wellcome, britain, leap fund, pharma
The London-based biomedical research charity the Wellcome Trust, Britain’s wealthiest foundation, has announced the launch of a new £250 million …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
